Open AccessSurvival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer
Author(s) -
Aranzazu Fernández-Martínez,
I.E. Krop,
D.W. Hillman,
M.-Y. Polley,
J.S. Parker,
L. Huebner,
K.A. Hoadley,
J. Shepherd,
S. Tolaney,
N. Lynn Henry,
C. Dang,
L. Harris,
D. Berry,
O. Hahn,
C. Hudis,
E. Winer,
A. Partridge,
C.M. Perou,
L.A. Carey
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/5xyh-n336
Subject(s) - trastuzumab , lapatinib , paclitaxel , medicine , oncology , breast cancer , cancer